Tag: MONOGRAPH

  • Abaloparatide

    Synthetic parathyroid hormone-related protein (PTHrP) analog and selective PTH1 receptor agonist with preferential RG-conformation binding

    A 34-amino-acid synthetic analog of human parathyroid hormone-related protein (1-34) engineered for selective activation of the RG conformation of the PTH type 1 receptor, producing transient osteoanabolic cAMP signaling with reduced bone resorption and hypercalcemia relative to teriparatide, approved for the treatment of osteoporosis in postmenopausal women and men at high fracture risk.

    Abstract

    Abaloparatide (BA058) is a synthetic 34-amino-acid peptide analog of human parathyroid hormone-related protein (PTHrP) (1-34) that acts as a selective agonist at the parathyroid hormone type 1 receptor (PTH1R), a class B G protein-coupled receptor expressed on osteoblasts and osteocytes. The compound was rationally designed to exploit conformational selectivity at PTH1R: abaloparatide binds the G protein-coupled RG conformation with an IC50 of approximately 0.20 nM and the G protein-independent R0 conformation with an IC50 of approximately 316 nM, yielding a 1,600-fold RG/R0 selectivity ratio that exceeds native PTHrP(1-36) (110-fold), native PTH(1-34) (12-fold), and the long-acting analog LA-PTH (2.2-fold). This selectivity produces a transient downstream cAMP signaling response following receptor activation, which, when delivered as a once-daily intermittent subcutaneous injection, preferentially stimulates osteoblast-mediated bone formation with lesser stimulation of osteoclast-mediated bone resorption and a lower incidence of hypercalcemia than teriparatide (recombinant PTH(1-34)), the first-in-class parathyroid hormone receptor agonist for osteoporosis.

    The compound shares 76% amino acid sequence homology with native PTHrP(1-34) and 41% homology with native PTH(1-34). The first 22 amino acids are identical to PTHrP(1-22); positions 23 through 34 carry eight substitutions, including an alpha-aminoisobutyric acid (Aib) residue at position 29, introduced to constrain the C-terminal alpha-helix and enhance peptide stability and receptor binding selectivity. The molecular formula is C174H300N56O49 with a molecular weight of approximately 3,960 daltons. Pharmacokinetics after subcutaneous dosing are characterized by rapid absorption (median Tmax approximately 0.51 hours), an absolute bioavailability of approximately 36%, a volume of distribution of approximately 50 liters, plasma protein binding of approximately 70%, and an elimination half-life of approximately 1 hour, with clearance proceeding through nonspecific proteolytic degradation to smaller peptide fragments followed by renal excretion.

    The subsequent ACTIVExtend trial demonstrated that sequential treatment with abaloparatide followed by alendronate maintained fracture risk reduction and further increased bone mineral density over a combined 43-month observation period. The ATOM trial extended efficacy to men with osteoporosis, demonstrating lumbar spine bone mineral density gains of 8.48% versus 1.17% on placebo at 12 months. The compound received United States Food and Drug Administration approval on April 28, 2017, for postmenopausal women with osteoporosis at high fracture risk (marketed as Tymlos), with an expanded indication for men with osteoporosis approved in December 2022. European Medicines Agency approval was granted in December 2022 under the trade name Eladynos. A transdermal solid microstructured transdermal system (sMTS) formulation is in clinical development as an alternative to subcutaneous injection. Treatment duration is limited to a cumulative lifetime maximum of 2 years owing to a dose- and time-dependent increase in osteosarcoma incidence observed in preclinical rodent carcinogenicity studies, a class effect shared with teriparatide.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Acetyl Glutathione

    S-acyl thioester prodrug of reduced glutathione (gamma-L-glutamyl-L-cysteinyl-glycine)

    An acetylated thioester derivative of reduced glutathione engineered to resist gastrointestinal hydrolysis and deliver intact glutathione equivalents to the intracellular compartment via passive membrane permeation and subsequent cytoplasmic thioesterase-mediated deacetylation.

    Abstract

    S-Acetyl-L-glutathione (SAG) is the S-acyl thioester of reduced glutathione (GSH) in which a single acetyl group is conjugated to the sulfhydryl moiety of the cysteine residue, shielding it from oxidation and enzymatic degradation during gastrointestinal transit and systemic circulation. The modification addresses the central pharmacokinetic limitation of oral GSH supplementation: native reduced glutathione is rapidly hydrolyzed by gamma-glutamyltransferase and dipeptidases in the intestinal lumen and brush border, resulting in less than 1 percent systemic bioavailability of the intact tripeptide after oral dosing in humans. By masking the reactive thiol as a thioester, SAG transits the gut mucosa substantially intact, permeates cell membranes by passive diffusion, and is deacetylated intracellularly by cytoplasmic thioesterases to regenerate free reduced glutathione, thereby replenishing the intracellular GSH pool without dependence on de novo synthesis from precursor amino acids.

    The compound was first described in the medicinal chemistry literature as a glutathione S-acyl derivative in the 1970s, with early characterization of its sensitivity to human liver esterases. It entered the nutraceutical research field in the 2000s as a candidate oral glutathione delivery vehicle and has since been the subject of a single-center, single-dose, randomized, open-label, cross-over pharmacokinetic trial in 18 healthy volunteers (Fanelli et al., 2018), multiple preclinical studies in hepatoprotection and oncology, and a comprehensive toxicological safety assessment including bacterial reverse mutation assay, in vitro micronucleus testing, acute oral toxicity, and 13-week repeated-dose oral toxicity studies. The pharmacokinetic trial demonstrated that SAG is rapidly deacetylated to GSH after oral administration, with no quantifiable SAG detected in plasma at any time point; plasma GSH concentrations after SAG administration exhibited higher maximum concentration (Cmax) and area under the curve (AUC) compared to an equimolar dose of a marketed reduced glutathione product, with mean relative bioavailability exceeding that of the reference formulation.

    Preclinical pharmacology has demonstrated hepatoprotective activity against carbon tetrachloride-induced liver injury through restoration of superoxide dismutase activity, glutathione peroxidase activity, and mitochondrial function, with concurrent suppression of the TLR4/NF-kappaB inflammatory cascade and reduction of proinflammatory cytokines TNF-alpha, IL-6, IL-1beta, and MCP-1. In oncology research, SAG selectively induces apoptosis in human lymphoma cell lines (Daudi, Raji, Jurkat) through a paradoxical intracellular GSH depletion mechanism while sparing normal lymphocytes and resistant lymphoma lines (Hut-78), a selectivity that has positioned it as a research tool for mechanism-based apoptosis investigation. The compound is manufactured by selective S-acetylation of reduced glutathione, achievable in a single step with cobalt chloride catalysis in dimethylformamide-trifluoroacetic acid solvent at yields exceeding 90 percent, and is commercially available from multiple research-grade suppliers at purities exceeding 98 percent by HPLC. It is supplied as a white to off-white crystalline powder with a molecular weight of 349.36 g/mol (CAS 3054-47-5), melting point of approximately 202 to 208 degrees Celsius, and stability at ambient temperature in dry storage. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Adamax

    Synthetic melanocortin-derived nootropic peptide with dual N-acetyl and C-terminal adamantane modifications for enhanced blood-brain barrier permeability and neurotrophic factor modulation

    A next-generation ACTH(4-10) analog engineered from Semax with N-terminal acetylation and C-terminal adamantylglycine amidation, designed to extend plasma half-life and central nervous system bioavailability while preserving the parent compound’s neurotrophic, neuroprotective, and monoaminergic pharmacology.

    Abstract

    Adamax (N-Acetyl Semax-Adamantane; Ac-MEHFPGP-AdaGly-NH2) is a synthetic nonapeptide research compound derived from Semax, the Russian-developed ACTH(4-10) analog approved in the Russian Federation for the treatment of ischemic stroke and cognitive impairment. The compound incorporates two structural modifications to the Semax backbone (Met-Glu-His-Phe-Pro-Gly-Pro): an N-terminal acetyl group that shields the peptide from aminopeptidase degradation and a C-terminal adamantylglycine amide that increases lipophilicity, enhances blood-brain barrier penetration, and confers resistance to carboxypeptidase cleavage. These modifications extend the effective half-life from approximately 30 to 60 minutes (Semax) to an estimated 8 to 10 hours and increase central nervous system bioavailability, enabling single daily dosing protocols in research applications.

    The pharmacological rationale for Adamax rests on the established molecular pharmacology of its parent compound Semax and on the broader adamantane medicinal chemistry literature. Semax activates brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) signaling in the hippocampus and basal forebrain, modulates melanocortin-3 and melanocortin-4 receptor (MC3R/MC4R) activity in cortical and hypothalamic circuits, and enhances dopaminergic and serotonergic neurotransmission in the striatum and prefrontal cortex [1, 2, 3]. Adamax preserves this multi-target pharmacology while the adamantane cage, a rigid tricyclo[3.3.1.1(3,7)]decane hydrocarbon scaffold shared with the FDA-approved drugs amantadine and memantine, confers the lipophilicity necessary for passive transcellular blood-brain barrier transit and reduces the susceptibility of the C-terminus to exopeptidase degradation [4, 5].

    Adamax does not have independent, peer-reviewed clinical or preclinical pharmacology publications indexed in PubMed or comparable biomedical databases as of the date of this monograph. All mechanistic characterization is inferred from the extensive published literature on Semax (over 300 publications, predominantly in Russian-language journals with a growing English-language subset), from the P21 (P021) adamantane-modified neurotrophic peptide literature, and from the structure-activity relationships of the ACTH(4-10) melanocortin fragment class. The compound is sold as a research-grade preparation by multiple peptide suppliers and has been identified as a designer peptide in border seizures by the New Zealand Medicines and Medical Devices Safety Authority [6]. It is not approved by any regulatory agency for therapeutic use. Investigators should treat all pharmacological claims as extrapolations from parent-compound data until independent Adamax-specific studies are published. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Agomelatine

    Melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2C receptor antagonism

    A naphthalenic melatonin analog developed at Servier as the first non-monoaminergic antidepressant, distinguished by dual melatonergic agonism and serotonin 5-HT2C antagonism that resynchronizes disrupted circadian rhythms while enhancing frontocortical dopaminergic and noradrenergic transmission.

    Abstract

    Agomelatine (S 20098) is a naphthalenic analog of melatonin and the first clinically approved antidepressant whose mechanism of action does not rely on direct modulation of monoamine reuptake or degradation. Developed by Servier Laboratories and granted European marketing authorization in 2009 under the trade names Valdoxan and Thymanax, agomelatine acts through high-affinity agonism at the melatonin MT1 and MT2 G-protein-coupled receptors (Ki approximately 0.1 nanomolar) combined with neutral antagonism at the serotonin 5-HT2C receptor (Ki approximately 630 nanomolar), a pharmacological profile that is unique among marketed antidepressants and that produces a synergistic downstream effect on circadian rhythm resynchronization, frontocortical dopamine and norepinephrine release, hippocampal neurogenesis, and brain-derived neurotrophic factor (BDNF) expression. The compound does not bind serotonin transporters, norepinephrine transporters, dopamine transporters, or any of the receptor families (muscarinic, histaminergic, adrenergic, GABAergic, glutamatergic, opioid) that produce the common adverse-event signatures of the selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, and tricyclic antidepressant classes, and consequently exhibits a tolerability profile characterized by the absence of sexual dysfunction, weight gain, discontinuation syndrome, and serotonin syndrome risk that distinguishes it from essentially all other antidepressant classes.

    Relapse prevention has been demonstrated in a 24-week extension study with significantly lower cumulative relapse rate on agomelatine (24 percent) compared to placebo (50 percent). A separate clinical evidence base supports efficacy in generalized anxiety disorder, with randomized placebo-controlled trials demonstrating superiority on the Hamilton Anxiety Rating Scale and comparable efficacy to escitalopram with superior sleep restoration.

    Pharmacokinetics are dominated by extensive hepatic first-pass metabolism through cytochrome P450 1A2 (CYP1A2, accounting for approximately 90 percent of clearance) and CYP2C9/CYP2C19 (approximately 10 percent), producing an oral bioavailability of approximately 1 percent despite greater than 80 percent gastrointestinal absorption, a plasma elimination half-life of 1 to 2 hours, and high inter-individual variability driven principally by CYP1A2 activity. The major metabolites (3-hydroxy-agomelatine, 7-desmethyl-agomelatine, and 3-hydroxy-7-desmethyl-agomelatine) are pharmacologically inactive and are renally eliminated after conjugation. CYP1A2 induction by tobacco smoking reduces plasma concentrations three- to fourfold; strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) increase exposure by up to 60-fold and are contraindicated in concurrent use.

    Serious hepatic reactions including cytolytic hepatitis and rare hepatic failure have been reported in postmarketing surveillance. Regulatory authorities require liver function testing before treatment initiation, at approximately 3, 6, 12, and 24 weeks of treatment, and at dose increase. Withdrawal of agomelatine leads to rapid normalization of transaminases in essentially all reported cases. The compound is contraindicated in patients with hepatic impairment.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Agmatine

    Endogenous polyamine neuromodulator with multi-target activity at NMDA receptors, imidazoline receptors, alpha-2 adrenoceptors, and nitric oxide synthase

    A decarboxylated arginine metabolite and endogenous neuromodulator distinguished by concurrent NMDA receptor channel blockade, imidazoline receptor agonism, selective inducible nitric oxide synthase inhibition, and alpha-2 adrenoceptor activation, with emerging clinical evidence in neuropathic pain, depression, and neuroprotection.

    Abstract

    Agmatine (4-aminobutylguanidine) is an endogenous cationic amine produced by the decarboxylation of L-arginine via the mitochondrial enzyme arginine decarboxylase. First isolated in 1910 by the Nobel laureate Albrecht Kossel from herring sperm protamine hydrolysates, agmatine was rediscovered in 1994 as an endogenous mammalian neuromodulator synthesized, stored in synaptic vesicles, and released in a calcium-dependent manner from neurons in the hippocampus, hypothalamus, locus coeruleus, and other brain regions. The compound operates through a pharmacologically unusual multi-target profile: it produces voltage-dependent blockade of NMDA receptor-gated cation channels at an intrachannel pore site (IC50 approximately 300 micromolar); it binds with high affinity to imidazoline I1 receptors (Kd approximately 0.7 micromolar) and I2 receptors (Kd approximately 1 micromolar); it activates alpha-2 adrenoceptors (Kd approximately 4 micromolar); and it competitively inhibits inducible nitric oxide synthase (Ki approximately 220 micromolar) with selectivity over the neuronal and endothelial isoforms. This composite mechanism produces neuroprotective, analgesic, antidepressant, and anti-inflammatory activity across a broad range of preclinical models, including excitotoxic and ischemic neuronal injury, traumatic brain injury, neuropathic and inflammatory pain, and behavioral models of depression and anxiety.

    A pilot open-label case series in painful small fiber neuropathy reported approximately 46 percent mean pain reduction over two months at the same dose [2]. A 2026 prospective open-label case series at Massachusetts General Hospital reported preliminary evidence for agmatine sulfate augmentation in treatment-resistant obsessive-compulsive disorder, with 40 percent of patients achieving clinically meaningful improvement on the Yale-Brown Obsessive Compulsive Scale [3]. Preclinical antidepressant-like activity has been demonstrated in the forced swimming test and tail suspension test across multiple laboratories, mediated through NMDA receptor blockade, nitric oxide synthase inhibition, and AMPA receptor and mTOR signaling activation. The compound modulates opioid pharmacology in a biphasic manner: it potentiates acute morphine analgesia while preventing the development of analgesic tolerance and physical dependence, a profile that has attracted substantial research interest in the context of the opioid crisis.

    Safety data are favorable. Clinical trial adverse events have been limited to mild, transient gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort) at the highest studied doses. The compound is commercially available as a dietary supplement (agmatine sulfate) in multiple jurisdictions. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Amitriptyline

    Tricyclic dibenzocycloheptadiene antidepressant with serotonin-norepinephrine reuptake inhibition and multi-target ion channel modulation

    A first-generation tricyclic antidepressant developed at Merck in the late 1950s, distinguished from later monoamine reuptake inhibitors by broad receptor polypharmacology spanning serotonin and norepinephrine transporters, voltage-gated sodium channels, NMDA receptors, histamine H1, muscarinic acetylcholine, and alpha-1 adrenergic receptors, supporting clinical applications across major depression, neuropathic pain, migraine prophylaxis, fibromyalgia, and irritable bowel syndrome.

    Abstract

    Amitriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine) is a first-generation tricyclic antidepressant (TCA) and the second member of the tricyclic class to reach the market, approved by the United States Food and Drug Administration in 1961 for the treatment of major depressive disorder. Originally developed at Merck Sharp and Dohme as a structural analog of imipramine in which the diamine bridge nitrogen is replaced by an exocyclic propylidene chain, amitriptyline inhibits the serotonin transporter (SERT) and norepinephrine transporter (NET) with low-nanomolar affinity for both targets (Ki approximately 3.1 nM for SERT, 19 nM for NET), producing dual monoamine reuptake inhibition that is mechanistically ancestral to the modern selective serotonin-norepinephrine reuptake inhibitors. Amitriptyline is distinguished from the SSRIs and SNRIs, however, by extensive polypharmacology at secondary targets: the compound acts as a potent antagonist at histamine H1 receptors (Ki approximately 1.1 nM), muscarinic acetylcholine receptors (Ki approximately 14 nM), and alpha-1 adrenergic receptors (Ki approximately 24 nM); as a use-dependent blocker of voltage-gated sodium channels through binding at the local anesthetic receptor site; and as an open-channel blocker of NMDA-type glutamate receptors with an IC50 in the low-micromolar range. This composite receptor profile produces the broad clinical utility of amitriptyline but also the anticholinergic, sedative, and cardiovascular adverse-event burden that has driven displacement by narrower-spectrum agents in the primary antidepressant indication.

    Despite the decline of tricyclic antidepressant prescribing for depression in the SSRI era, amitriptyline remains one of the most widely prescribed medications worldwide. The World Health Organization lists amitriptyline on its Model List of Essential Medicines. The compound is a first-line treatment for neuropathic pain in multiple international guidelines (NICE, AAN, NeuPSIG), supported by decades of randomized controlled trial evidence in painful diabetic neuropathy, postherpetic neuralgia, and mixed neuropathic pain syndromes. The 2022 OPTION-DM trial, the largest head-to-head crossover neuropathic pain trial ever conducted, demonstrated equivalent analgesic efficacy of amitriptyline, duloxetine, and pregabalin monotherapy in diabetic peripheral neuropathic pain, with combination therapy producing superior analgesia. Amitriptyline is recommended for migraine prophylaxis (NNT approximately 3 to 4 for 50 percent headache frequency reduction) and for fibromyalgia analgesia, and it retains clinical use in tension-type headache, insomnia comorbid with chronic pain, nocturnal enuresis, and selected anxiety disorders.

    Pharmacokinetics are dominated by hepatic metabolism through two principal cytochrome P450 pathways: CYP2C19-mediated N-demethylation to the active metabolite nortriptyline (itself a potent and selective NET inhibitor) and CYP2D6-mediated hydroxylation to 10-hydroxymetabolites that are subsequently glucuronidated and renally excreted. Both CYP2C19 and CYP2D6 exhibit clinically significant genetic polymorphism. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing guidelines for amitriptyline indexed to CYP2D6 and CYP2C19 genotype, recommending dose reduction or alternative agent selection in CYP2D6 poor metabolizers and CYP2C19 ultrarapid metabolizers. Plasma elimination half-life ranges from 10 to 28 hours across the population; oral bioavailability is approximately 45 percent owing to substantial first-pass hepatic metabolism.

    Amitriptyline has a narrow therapeutic index; ingestion of 10 to 20 mg/kg is potentially life-threatening through sodium channel blockade producing cardiac conduction delay, ventricular dysrhythmias, and myocardial depression. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Anastrozole

    Third-generation nonsteroidal aromatase inhibitor (triazole derivative)

    A potent, selective, reversible nonsteroidal aromatase inhibitor developed at Zeneca Pharmaceuticals for the adjuvant treatment of estrogen receptor-positive breast cancer, distinguished from steroidal inactivators by triazole-mediated competitive binding, oral bioavailability, and a long terminal half-life permitting once-daily dosing.

    Abstract

    Anastrozole (ZD1033, Arimidex) is a third-generation nonsteroidal aromatase inhibitor of the triazole class that selectively and reversibly inhibits the cytochrome P450 19A1 (CYP19A1, aromatase) enzyme complex responsible for the terminal step in estrogen biosynthesis: the conversion of androstenedione to estrone and testosterone to estradiol. The compound was developed at Zeneca Pharmaceuticals (now AstraZeneca) through systematic optimization of triazole-bearing aromatase inhibitor scaffolds and received United States Food and Drug Administration approval in 1995 for the treatment of advanced breast cancer in postmenopausal women following tamoxifen therapy, with subsequent label expansions to first-line advanced disease (2000) and adjuvant treatment of early-stage hormone receptor-positive breast cancer (2002).

    The pivotal Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, enrolling 9,366 postmenopausal women with early-stage invasive breast cancer, established anastrozole as superior to tamoxifen on disease-free survival, time to recurrence, time to distant recurrence, and incidence of contralateral breast cancer at 100-month and 10-year analyses, with a carryover benefit extending beyond the 5-year treatment period. Anastrozole is now among the most widely prescribed endocrine therapies in oncology, with established roles in adjuvant, neoadjuvant, extended adjuvant, and chemoprevention settings for estrogen receptor-positive breast cancer.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 2 hours), high oral bioavailability (approximately 85 percent), extensive hepatic metabolism through N-dealkylation, hydroxylation, and glucuronidation (with a principal inactive triazole metabolite), and a long terminal elimination half-life of 40 to 50 hours that supports once-daily dosing and achieves steady-state plasma concentrations within approximately 7 days. Anastrozole is not a potent inhibitor or inducer of cytochrome P450 enzymes at therapeutic concentrations, and clinically significant drug-drug interactions are uncommon. The compound is well tolerated; the principal adverse events are hot flashes, arthralgia, fatigue, and musculoskeletal stiffness, with the most clinically significant long-term safety signal being accelerated bone mineral density loss and increased fracture risk attributable to profound estrogen suppression, managed in clinical practice through concurrent bisphosphonate therapy and bone density monitoring.

    Beyond the oncology indication, anastrozole has been investigated as an off-label research tool for modulating the hypothalamic-pituitary-gonadal axis in males, where aromatase inhibition reduces the conversion of testosterone to estradiol, relieves estrogen-mediated negative feedback on gonadotropin secretion, and increases endogenous testosterone production. This application remains investigational and is not approved by regulatory authorities. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • ABT-737

    BH3 mimetic inhibitor of anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, Bcl-w)

    A potent, cell-permeable BH3-mimetic small molecule developed at Abbott Laboratories by fragment-based drug design, capable of high-affinity binding to the hydrophobic groove of Bcl-2, Bcl-xL, and Bcl-w to displace pro-apoptotic BH3-only proteins and trigger Bak/Bax-dependent mitochondrial apoptosis in Bcl-2-dependent tumor cells and senescent cells.

    Abstract

    ABT-737 is a rationally designed BH3 mimetic small molecule that binds with sub-nanomolar affinity (Ki less than 1 nM) to the BH3-binding groove of the anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w, displacing sequestered pro-apoptotic effectors (Bax, Bak) and BH3-only activators (Bid, Bim) to trigger the intrinsic mitochondrial apoptotic pathway [1]. Developed at Abbott Laboratories (now AbbVie) and reported by Oltersdorf et al. in 2005, ABT-737 was the product of a landmark structure-activity relationships by nuclear magnetic resonance (SAR-by-NMR) fragment-based drug discovery campaign in which two small-molecule fragments identified by NMR chemical shift perturbation screening against Bcl-xL were chemically linked and iteratively optimized by parallel synthesis and X-ray crystallography-guided design to yield a compound approximately three orders of magnitude more potent than any prior Bcl-2 family inhibitor [1, 2]. The compound binds weakly (Ki greater than 460 nM) to the structurally related anti-apoptotic proteins Mcl-1 and Bfl-1/A1, a selectivity gap that defines both the therapeutic window and the principal resistance mechanism observed across tumor models.

    In preclinical studies, ABT-737 demonstrated potent single-agent antitumor activity in xenograft models of small-cell lung cancer (SCLC), follicular lymphoma, and chronic lymphocytic leukemia (CLL), producing complete tumor regressions in SCLC models derived from H146 and H187 cell lines and inducing rapid apoptosis in primary CLL cells at an EC50 of approximately 7 nM [1, 3, 4]. Activity extends to acute myeloid leukemia (AML) blasts and leukemia stem cells, multiple myeloma cell lines with Bcl-2 dependence, and several solid tumor models in combination with conventional chemotherapy or targeted agents [5, 6, 7]. The compound preferentially induces apoptosis in malignant cells while showing reduced activity against normal hematopoietic progenitors at equivalent concentrations, a selectivity attributed to the elevated Bcl-2 dependence of transformed cells relative to their normal counterparts.

    A critical limitation of ABT-737 is its lack of oral bioavailability and poor aqueous solubility, properties that confined it to parenteral administration in preclinical models and precluded direct clinical development [1]. These pharmacokinetic constraints motivated the subsequent design of navitoclax (ABT-263), an orally bioavailable analog with equivalent target selectivity, and ultimately venetoclax (ABT-199), a Bcl-2-selective derivative that eliminated the dose-limiting thrombocytopenia caused by Bcl-xL inhibition in platelets [8, 9]. Venetoclax received FDA approval in 2016 for CLL and subsequently for AML, validating the therapeutic hypothesis that ABT-737 established preclinically.

    Beyond oncology, ABT-737 has been characterized as a senolytic agent capable of selectively clearing senescent cells through disruption of the Bcl-2/Bcl-xL-dependent survival program that senescent cells upregulate as part of the senescence-associated anti-apoptotic phenotype (SAAP) [10]. Administration of ABT-737 during the second half of life in progeroid mouse models abrogated senescence markers and increased median survival, extending the compound’s research relevance to aging biology, fibrosis, and tissue regeneration [10, 11].

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Amantadine

    Adamantane-derived multi-target neurotherapeutic agent with weak NMDA receptor antagonism, sigma-1 receptor agonism, and indirect dopaminergic activity

    A tricyclic adamantane amine originally developed as an influenza A antiviral, subsequently repositioned for Parkinson’s disease and levodopa-induced dyskinesia, distinguished by a polypharmacological profile spanning NMDA receptor antagonism, sigma-1 receptor agonism, dopaminergic facilitation, and nicotinic acetylcholine receptor modulation.

    Abstract

    Amantadine (1-adamantanamine) is a small-molecule adamantane derivative that has undergone three distinct phases of clinical development since its original synthesis in the 1960s: as the first synthetic antiviral agent active against influenza A virus through blockade of the M2 ion channel protein; as an antiparkinsonian agent discovered serendipitously in 1968 and subsequently approved for the treatment of drug-induced extrapyramidal reactions and as adjunctive therapy in Parkinson’s disease; and, most recently, as a delayed-release and extended-release formulation (Gocovri) approved by the United States Food and Drug Administration in 2017 for the treatment of levodopa-induced dyskinesia in Parkinson’s disease. The compound occupies a distinctive position in clinical neuropharmacology by virtue of a polypharmacological profile that engages multiple molecular targets at therapeutically relevant concentrations. At the sigma-1 receptor, amantadine acts as an agonist with a Ki of approximately 7.44 micromolar, a mechanism that has been linked to the modulation of dopaminergic neurotransmission including enhancement of tyrosine hydroxylase activity, facilitation of striatal dopamine release, and inhibition of dopamine reuptake. The compound also functions as a negative allosteric modulator of alpha-4-beta-2 and alpha-7 nicotinic acetylcholine receptors, with IC50 values in the low-micromolar range, and exerts additional effects on potassium channels, aromatic amino acid decarboxylase, and glial-cell-derived neurotrophic factor expression.

    The clinical evidence base for amantadine now spans six decades and includes approved indications in Parkinson’s disease (both as monotherapy for mild symptoms and as adjunctive therapy for levodopa-induced dyskinesia), drug-induced extrapyramidal reactions, and influenza A prophylaxis and treatment (now largely obsolete owing to widespread viral resistance). Off-label applications with meaningful clinical support include acceleration of functional recovery in traumatic brain injury with disorders of consciousness, as demonstrated in the landmark Giacino et al. (2012) randomized placebo-controlled trial published in the New England Journal of Medicine; management of fatigue in multiple sclerosis; and reduction of chorea in Huntington disease. Pharmacokinetics are characterized by high oral bioavailability (86 to 90 percent), minimal hepatic metabolism with predominantly renal excretion of unchanged drug, a plasma elimination half-life of approximately 12 hours in subjects with normal renal function (extending to 7 to 10 days in severe renal impairment), and the absence of significant cytochrome P450 involvement. The adverse-event profile includes central nervous system effects (insomnia, dizziness, hallucinations, confusion), peripheral edema, the distinctive dermatological finding of livedo reticularis, and, at supratherapeutic doses or in overdose, QT prolongation and cardiac arrhythmias. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.